SCHEMBL19429488

SCHEMBL19429488

CC(C)c1cc2c([nH]c1=O)CCCC2=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKN1 Q16512 1/20 0.44
PKN2 Q16513 1/20 0.44
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MAPT P10636 2/20 0.35
NPSR1 Q6W5P4 2/20 0.34
MEN1 O00255 1/20 0.34
MAPK1 P28482 1/20 0.34
KMT2A Q03164 1/20 0.34
PIM1 P11309 1/20 0.33
PIM2 Q9P1W9 1/20 0.33
TSHR P16473 1/20 0.33
PTK2 Q05397 2/20 0.33
CHEK1 O14757 1/20 0.33
AURKA O14965 1/20 0.33
MAP4K4 O95819 1/20 0.33
ABL1 P00519 1/20 0.33
CSF1R P07333 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21923004 0.82 PKN1 (0.39) PKN1PKN2KDM4EALDH1A1HPGD
SCHEMBL22035221 0.79 KDM4E (0.49) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL22944303 0.79 PKN1 (0.46) PKN1PKN2KDM4EALDH1A1HPGD
SCHEMBL21785533 0.78 KDM4E (0.51) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL26756604 0.78 KDM4E (0.51) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL21785849 0.78 KDM4E (0.51) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL9802586 0.77 PKN1 (0.47) PKN1PKN2KDM4EALDH1A1HPGD
SCHEMBL19403843 0.76 PKN1 (0.41) PKN1PKN2KDM4EALDH1A1HPGD
SCHEMBL19429469 0.75 PKN1 (0.45) PKN1PKN2KDM4EALDH1A1HPGD
SCHEMBL19398116 0.73 PKN1 (0.44) PKN1PKN2KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780835-B2 Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases ARRAY BIOPHARMA INC. (US) 2023-10-10 US disclosed
US-20230011441-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC. (US) 2023-01-12 US disclosed
US-20210147430-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS INCYTE CORPORATION 2021-05-20 US disclosed
US-10844069-B2 Pyrrolotriazine compounds as TAM inhibitors INCYTE CORPORATION (US) 2020-11-24 US disclosed
US-20200131185-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS INCYTE CORPORATION 2020-04-30 US disclosed
US-10442810-B2 Pyrrolotriazine compounds as TAM inhibitors INCYTE CORPORATION (US) 2019-10-15 US disclosed
WO-2017172596-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS INCYTE CORPORATION (US) 2017-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230011441-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES RET, MERTK, MET PKN1 142/4885PKN2 77/4885KDM4E 935/4885
US-20210147430-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS MERTK, MAP3K15, MAP3K5 PKN1 446/4885PKN2 441/4885KDM4E 769/4885
US-10844069-B2 Pyrrolotriazine compounds as TAM inhibitors MERTK, MAP3K15, MAP3K5 PKN1 446/4885PKN2 441/4885KDM4E 769/4885
US-20200131185-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS MERTK, MAP3K15, MAP3K5 PKN1 446/4885PKN2 441/4885KDM4E 769/4885
US-10442810-B2 Pyrrolotriazine compounds as TAM inhibitors MERTK, MAP3K15, MAP3K5 PKN1 446/4885PKN2 441/4885KDM4E 769/4885
US-11780835-B2 Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases RET, MERTK, MET PKN1 142/4885PKN2 77/4885KDM4E 935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.